Neurogene to Participate in Upcoming Conferences
June 05 2024 - 7:30AM
Business Wire
Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded
to bring life-changing genetic medicines to patients and families
affected by rare neurological diseases, today announced that
Company management will participate in the following
conferences:
Goldman Sachs 45th Annual Global Healthcare Conference
Format: Management will present a corporate overview and
participate in investor meetings Date: Wednesday, June 12 at 1:20
p.m. ET
2024 IRSF (International Rett Syndrome Foundation) Rett
Syndrome Scientific Meeting Format: Management and Bernhard
Suter, M.D., Medical Director of the Blue Bird Circle Rett Center
at Texas Children’s Hospital, Associate Professor of Pediatrics and
Neurology at Baylor College of Medicine, and principal investigator
in the Phase 1/2 NGN-401 gene therapy trial for Rett syndrome, will
present interim safety data from the NGN-401 trial Date: Tuesday,
June 18 at 5:15 p.m. MT (poster presentation), and Wednesday, June
19 at 11:30 a.m. MT (oral presentation)
TD Cowen Genetic Medicines & RNA Summit Format:
Management will participate in a fireside chat Date: Friday, June
21 at 10:40 a.m. ET
Live webcasts of the corporate overview and fireside chat will
be accessible from the Investor Relations section of Neurogene’s
website under events, where a replay of the events will also be
available for a limited time.
About Neurogene The mission of Neurogene is to treat
devastating neurological diseases to improve the lives of patients
and families impacted by these rare diseases. Neurogene is
developing novel approaches and treatments to address the
limitations of conventional gene therapy in central nervous system
disorders. This includes selecting a delivery approach to maximize
distribution to target tissues and designing products to maximize
potency and purity for an optimized efficacy and safety profile.
The Company’s novel and proprietary EXACT transgene regulation
platform technology allows for the delivery of therapeutic levels
while limiting transgene toxicity associated with conventional gene
therapy. Neurogene has constructed a state-of-the-art gene therapy
manufacturing facility in Houston, Texas. CGMP production of
NGN-401 was conducted in this facility and is expected to support
pivotal clinical development activities. For more information,
visit www.neurogene.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240605485474/en/
Company: Cara Mayfield Vice President, Corporate Affairs
cara.mayfield@neurogene.com
Investor: Melissa Forst Argot Partners
Neurogene@argotpartners.com
Neurogene (NASDAQ:NGNE)
Historical Stock Chart
From Nov 2024 to Dec 2024
Neurogene (NASDAQ:NGNE)
Historical Stock Chart
From Dec 2023 to Dec 2024